CoChat

A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Delta-like protein 3 (DLL3) is highly expressed in solid tumors, including neuroendocrine carcinomas/neuroendocrine tumors (NEC/NET). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting antibody-drug conjugate. Patients with NECs and other advanced DLL3-expressing tumors were enrolled in this phase I/II study (NCT02709889). The primary endpoint was safety. Two hundred patients were enrolled: 101 with NEC/NET (large-cell NEC, gastroenteropancreatic NEC, neuroendocrine prostate cancer, and other NEC/NET) and 99 with other solid tumors (melanoma, medullary thyroid cancer [MTC], glioblastoma, and other). The recommended phase II dose (RP2D) was 0.3 mg/kg every 6 weeks (q6w) for two cycles. At the RP2D, grade 3/4 adverse events included anemia (17%), thrombocytopenia (15%), and elevated aspartate aminotransferase (8%). Responses were confirmed in 15/145 patients (10%) treated at 0.3 mg/kg, including 9/69 patients (13%) with NEC/NET. Rova-T at 0.3 mg/kg q6w had manageable toxicity, with antitumor activity observed in patients with NEC/NET, melanoma, MTC, and glioblastoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41698-021-00214-y

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 81

Metadata

Authors
Mansfield, A. S., Hong, D. S., Hann, C. L., Farago, A. F., Beltran, H., Waqar, S. N., Hendifar, A. E., Anthony, L. B., Taylor, M. H., Bryce, A. H., Tagawa, S. T., Lewis, K., Niu, J., Chung, C. H., Cleary, J. M., Rossi, M., Ludwig, C., Valenzuela, R., Luo, Y., & Aggarwal, R.
Affiliations
  • Mayo Clinic (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Johns Hopkins University (US)
  • Massachusetts General Hospital (US)
  • Dana-Farber Cancer Institute (US)
  • Washington University in St. Louis (US)
  • Cedars-Sinai Medical Center (US)
  • Albert B. Chandler Hospital (US)
  • Providence Portland Medical Center (US)
  • Mayo Clinic Hospital (US)
  • Weill Cornell Medicine (US)
  • University of Colorado Denver (US)
  • Banner MD Anderson Cancer Center (US)
  • Moffitt Cancer Center (US)
  • AbbVie (United States) (US)
  • University of California, San Francisco (US)
Corresponding author
Aggarwal, Rahul
Venue
npj Precision Oncology
Published
2021-08-05
Volume
5
Issue
1
Pages
74-74
ISSN
2397-768X (ISSN-L)
OpenAlex
W3189704246
Cited by
80
References
32
Citations by year
2026: 15 · 2025: 21 · 2024: 12 · 2023: 17 · 2022: 10 · 2021: 5
FWCI
7.93
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Precision Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
AbbVie
Topics
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
rovalpituzumab tesirine, DLL3, antibody-drug conjugates, neuroendocrine carcinoma, neuroendocrine tumors, advanced solid tumors, melanoma, medullary thyroid carcinoma, glioblastoma, recommended phase 2 dose, anticancer activity, adverse events, anemia, thrombocytopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors. https://app.cochat.ai/papers/10.1038/s41698-021-00214-y
The paper
Mansfield, A. S., Hong, D. S., Hann, C. L., Farago, A. F., Beltran, H., Waqar, S. N., Hendifar, A. E., Anthony, L. B., Taylor, M. H., Bryce, A. H., Tagawa, S. T., Lewis, K., Niu, J., Chung, C. H., Cleary, J. M., Rossi, M., Ludwig, C., Valenzuela, R., Luo, Y., & Aggarwal, R. (2021). A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors. npj Precision Oncology. https://doi.org/10.1038/s41698-021-00214-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.